Status:

NOT_YET_RECRUITING

A Safety and Performance Study of the Use of EmboBio for the Intra-arterial Treatment of Abdominopelvic Bleeding

Lead Sponsor:

Embobio Medical

Conditions:

Abdomino-pelvic Surgery

Bleeding

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This research conducted by EMBOBIO SAS is intended for patients with bleeding or at risk of bleeding in the abdominal-pelvic region requiring embolization. The EmboBio device (embolization implant) i...

Detailed Description

Abdominopelvic bleeding may occur in different and various circumstances, in a spontaneous way, after a trauma, in a neoplasic context, after a visceral aneurysm's rupture, during or after a surgical ...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Patient presenting with an arterial abdominopelvic bleeding or risk of bleeding requiring embolization with a permanent embolic agent, i.e. abdominal solid organs hemorrhage including angiomyolipoma, visceral aneurysms and pseudoaneurysms actively bleeding or at risk of bleeding (upper or lower gastrointestinal arteries), pelvic hemorrhage, postpartum hemorrhage in case of active leakage visualized by contrast media extravasation, soft tissue hemorrhage
  • Patient having provided a written informed consent

Exclusion

  • Known hypersensitivity to Agar-Agar
  • Known hypersensitivity to iodinated contrast media
  • Patient unable or unwilling to provide a written informed consent
  • Patient unable to provide informed consent due to his clinical condition
  • Patient participating in another interventional study
  • Patient implanted with Embobio device at a previous operating time
  • Vulnerable, pregnant, and breastfeeding population
  • Patient unwilling or unable to follow the study schedule
  • Patients unable to receive prior information on the clinical investigation due to the urgency of the situation
  • Target arteries diameter \> 2 mm
  • Vascular anatomy preventing proper placement of the catheter.
  • Arteriovenous shunts with a high flow rate or a diameter greater than 2 mm

Key Trial Info

Start Date :

October 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2027

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT07199348

Start Date

October 1 2025

End Date

April 1 2027

Last Update

September 30 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Safety and Performance Study of the Use of EmboBio for the Intra-arterial Treatment of Abdominopelvic Bleeding | DecenTrialz